SEARCH:   Advanced

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Maloney, D. Articles by Levy, R Search for Related Content PubMed PubMed Citation Articles by Maloney, D. Articles by Levy, R Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma DG Maloney, TM Liles, DK Czerwinski, C Waldichuk, J Rosenberg, A Grillo-Lopez and R Levy Department of Medicine, Stanford University Medical Center, CA. The B-cell antigen CD20 is expressed on normal B cells and by nearly all B-cell lymphomas. This nonmodulating antigen provides an excellent target for antibody-directed therapies. A chimeric anti-CD20 antibody (IDEC-C2B8), consisting of human IgG1-kappa constant regions and variable regions from the murine monoclonal anti-CD20 antibody IDEC- 2B8, has been produced for clinical trials. It lyses CD20+ cells in vitro via complement and antibody-dependent cell-mediated lysis. Preclinical studies have shown that the chimeric antibody selectively depletes B cells in blood and lymph nodes in macaque monkeys. In this phase I clinical trial, 15 patients (3 per dose level) with relapsed low-grade B-cell lymphoma were treated with a single dose (10, 50, 100, 250, or 500 mg/m2) of antibody administered intravenously. Treatment- related symptoms correlated with the number of circulating CD20 cells and grade II events consisted of fever (5 patients); nausea (2), rigor (2), orthostatic hypotension (2), bronchospasm (1), and thrombocytopenia (1). No significant toxicities were observed during the 3 months of follow-up. Serum C3, IgG, and IgM levels, neutrophils, and T cells were largely unchanged. At the three higher dose levels, pharmacokinetics of the free antibody showed a serum half-life of 4.4 days (range, 1.6 to 10.5). Levels greater than 10 micrograms/mL persisted in 6 of 9 patients for more than 14 days. No quantifiable immune responses to the infused antibody have been detected. CD20+ B cells were rapidly and specifically depleted in the peripheral blood at 24 to 72 hours and remained depleted for at least 2 to 3 months in most patients. Two-week postinfusion tumor biopsies showed the chimeric antibody bound to tumor cells and a decrease in the percentage of B cells. Tumor regressions occurred in 6 of 15 patients (2 partial and 4 minor responses). The results of this single-dose trial have been used to design a multiple-dose phase I/II study. Volume 84, Issue 8, pp. 2457-2466, 10/15/1994 Copyright © 1994 by The American Society of Hematology CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: D. Ennishi, H. Asai, Y. Maeda, K. Shinagawa, K. Ikeda, M. Yokoyama, Y. Terui, K. Takeuchi, T. Yoshino, K. Matsuo, et al. Statin-independent prognosis of patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy Ann. Onc., November 2, 2009; (2009) mdp490v1. [Abstract] [Full Text] [PDF] F. Morschhauser, J. P. Leonard, L. Fayad, B. Coiffier, M.-O. Petillon, M. Coleman, S. J. Schuster, M. J.S. Dyer, H. Horne, N. Teoh, et al. Humanized Anti-CD20 Antibody, Veltuzumab, in Refractory/Recurrent Non-Hodgkin's Lymphoma: Phase I/II Results J. Clin. Oncol., July 10, 2009; 27(20): 3346 - 3353. [Abstract] [Full Text] [PDF] N. A. Johnson, M. Boyle, A. Bashashati, S. Leach, A. Brooks-Wilson, L. H. Sehn, M. Chhanabhai, R. R. Brinkman, J. M. Connors, A. P. Weng, et al. Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival Blood, April 16, 2009; 113(16): 3773 - 3780. [Abstract] [Full Text] [PDF] N. A. Johnson, S. Leach, B. Woolcock, R. J. deLeeuw, A. Bashashati, L. H. Sehn, J. M. Connors, M. Chhanabhai, A. Brooks-Wilson, and R. D. Gascoyne CD20 mutations involving the rituximab epitope are rare in diffuse large B-cell lymphomas and are not a significant cause of R-CHOP failure Haematologica, March 1, 2009; 94(3): 423 - 427. [Abstract] [Full Text] [PDF] M. Siano, E. Lerch, L. Negretti, E. Zucca, D. Rodriguez-Abreu, M. Oberson, L. Leoncini, O. Mora, C. Sessa, A. Gallino, et al. A Phase I-II Study to Determine the Maximum Tolerated Infusion Rate of Rituximab with Special Emphasis on Monitoring the Effect of Rituximab on Cardiac Function Clin. Cancer Res., December 1, 2008; 14(23): 7935 - 7939. [Abstract] [Full Text] [PDF] X. Zhou, W. Hu, and X. Qin The Role of Complement in the Mechanism of Action of Rituximab for B-Cell Lymphoma: Implications for Therapy Oncologist, September 1, 2008; 13(9): 954 - 966. [Abstract] [Full Text] [PDF] B. D. Cheson and J. P. Leonard Monoclonal Antibody Therapy for B-Cell Non-Hodgkin's Lymphoma N. Engl. J. Med., August 7, 2008; 359(6): 613 - 626. [Full Text] [PDF] M. Q. Lacy, M. Alsina, R. Fonseca, M. L. Paccagnella, C. L. Melvin, D. Yin, A. Sharma, M. Enriquez Sarano, M. Pollak, S. Jagannath, et al. Phase I, Pharmacokinetic and Pharmacodynamic Study of the Anti-Insulinlike Growth Factor Type 1 Receptor Monoclonal Antibody CP-751,871 in Patients With Multiple Myeloma J. Clin. Oncol., July 1, 2008; 26(19): 3196 - 3203. [Abstract] [Full Text] [PDF] K. Shimada, K. Matsue, K. Yamamoto, T. Murase, N. Ichikawa, M. Okamoto, N. Niitsu, H. Kosugi, N. Tsukamoto, H. Miwa, et al. Retrospective Analysis of Intravascular Large B-Cell Lymphoma Treated With Rituximab-Containing Chemotherapy As Reported by the IVL Study Group in Japan J. Clin. Oncol., July 1, 2008; 26(19): 3189 - 3195. [Abstract] [Full Text] [PDF] G. D. Shah, J. Yahalom, D. D. Correa, R. K. Lai, J. J. Raizer, D. Schiff, R. LaRocca, B. Grant, L. M. DeAngelis, and L. E. Abrey Combined Immunochemotherapy With Reduced Whole-Brain Radiotherapy for Newly Diagnosed Primary CNS Lymphoma J. Clin. Oncol., October 20, 2007; 25(30): 4730 - 4735. [Abstract] [Full Text] [PDF] C. M. Shachaf, O. D. Perez, S. Youssef, A. C. Fan, S. Elchuri, M. J. Goldstein, A. E. Shirer, O. Sharpe, J. Chen, D. J. Mitchell, et al. Inhibition of HMGcoA reductase by atorvastatin prevents and reverses MYC-induced lymphomagenesis Blood, October 1, 2007; 110(7): 2674 - 2684. [Abstract] [Full Text] [PDF] N. Hosen, C. Y. Park, N. Tatsumi, Y. Oji, H. Sugiyama, M. Gramatzki, A. M. Krensky, and I. L. Weissman CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia PNAS, June 26, 2007; 104(26): 11008 - 11013. [Abstract] [Full Text] [PDF] J. G. Berdeja, A. Hess, D. M. Lucas, P. O'Donnell, R. F. Ambinder, L. F. Diehl, D. Carter-Brookins, S. Newton, and I. W. Flinn Systemic Interleukin-2 and Adoptive Transfer of Lymphokine-Activated Killer Cells Improves Antibody-Dependent Cellular Cytotoxicity in Patients with Relapsed B-Cell Lymphoma Treated with Rituximab Clin. Cancer Res., April 15, 2007; 13(8): 2392 - 2399. [Abstract] [Full Text] [PDF] S. S. Neelapu and L. W. Kwak Vaccine Therapy for B-Cell Lymphomas: Next-Generation Strategies Hematology, January 1, 2007; 2007(1): 243 - 249. [Abstract] [Full Text] [PDF] M. J. Leandro, N. Cooper, G. Cambridge, M. R. Ehrenstein, and J. C. W. Edwards Bone marrow B-lineage cells in patients with rheumatoid arthritis following rituximab therapy Rheumatology, January 1, 2007; 46(1): 29 - 36. [Abstract] [Full Text] [PDF] A. Charalambous, M. Oks, G. Nchinda, S. Yamazaki, and R. M. Steinman Dendritic Cell Targeting of Survivin Protein in a Xenogeneic Form Elicits Strong CD4+ T Cell Immunity to Mouse Survivin J. Immunol., December 15, 2006; 177(12): 8410 - 8421. [Abstract] [Full Text] [PDF] R. M. Sharkey and D. M. Goldenberg Targeted Therapy of Cancer: New Prospects for Antibodies and Immunoconjugates CA Cancer J Clin, July 1, 2006; 56(4): 226 - 243. [Abstract] [Full Text] [PDF] D. El Fassi, C. H Nielsen, H. C Hasselbalch, and L. Hegedus The rationale for B lymphocyte depletion in Graves' disease. Monoclonal anti-CD20 antibody therapy as a novel treatment option. Eur. J. Endocrinol., May 1, 2006; 154(5): 623 - 632. [Abstract] [Full Text] [PDF] O. Thaunat, M.-F. Mamzer-Bruneel, F. Agbalika, F. Valensi, M. Venditto, C. Lebbe, C. Frances, R. Kania, L. Chatenoud, C. Antoine, et al. Severe human herpesvirus-8 primary infection in a renal transplant patient successfully treated with anti-CD20 monoclonal antibody. Blood, April 1, 2006; 107(7): 3009 - 3010. [Full Text] [PDF] C. M. Bennett, Z. R. Rogers, D. D. Kinnamon, J. B. Bussel, D. H. Mahoney, T. C. Abshire, H. Sawaf, T. B. Moore, M. L. Loh, B. E. Glader, et al. Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura Blood, April 1, 2006; 107(7): 2639 - 2642. [Abstract] [Full Text] [PDF] R. H. Carter B Cells in Health and Disease Mayo Clin. Proc., March 1, 2006; 81(3): 377 - 384. [Abstract] [Full Text] [PDF] W. Wojciechowski, H. Li, S. Marshall, C. Dell'Agnola, and I. Espinoza-Delgado Enhanced Expression of CD20 in Human Tumor B Cells Is Controlled through ERK-Dependent Mechanisms J. Immunol., June 15, 2005; 174(12): 7859 - 7868. [Abstract] [Full Text] [PDF] S. D. Gillies, Y. Lan, S. Williams, F. Carr, S. Forman, A. Raubitschek, and K.-M. Lo An anti-CD20-IL-2 immunocytokine is highly efficacious in a SCID mouse model of established human B lymphoma Blood, May 15, 2005; 105(10): 3972 - 3978. [Abstract] [Full Text] [PDF] S. Muraro, A. Bondanza, M. Bellone, P. D. Greenberg, and C. Bonini Molecular modification of idiotypes from B-cell lymphomas for expression in mature dendritic cells as a strategy to induce tumor-reactive CD4+ and CD8+ T-cell responses Blood, May 1, 2005; 105(9): 3596 - 3604. [Abstract] [Full Text] [PDF] Y. Hamaguchi, J. Uchida, D. W. Cain, G. M. Venturi, J. C. Poe, K. M. Haas, and T. F. Tedder The Peritoneal Cavity Provides a Protective Niche for B1 and Conventional B Lymphocytes during Anti-CD20 Immunotherapy in Mice J. Immunol., April 1, 2005; 174(7): 4389 - 4399. [Abstract] [Full Text] [PDF] M. C. Milone, D. E. Tsai, R. L. Hodinka, L. B. Silverman, A. Malbran, M. A. Wasik, and K. E. Nichols Treatment of primary Epstein-Barr virus infection in patients with X-linked lymphoproliferative disease using B-cell-directed therapy Blood, February 1, 2005; 105(3): 994 - 996. [Abstract] [Full Text] [PDF] M. Zhang, Z. Zhang, C. K. Goldman, J. Janik, and T. A. Waldmann Combination therapy for adult T-cell leukemia-xenografted mice: flavopiridol and anti-CD25 monoclonal antibody Blood, February 1, 2005; 105(3): 1231 - 1236. [Abstract] [Full Text] [PDF] F. K. Stevenson, C. H. Ottensmeier, P. Johnson, D. Zhu, S. L. Buchan, K. J. McCann, J. S. Roddick, A. T. King, F. McNicholl, N. Savelyeva, et al. DNA vaccines to attack cancer PNAS, October 5, 2004; 101(suppl_2): 14646 - 14652. [Abstract] [Full Text] [PDF] K. Tobinai and T. Hotta Clinical Trials for Malignant Lymphoma in Japan Jpn. J. Clin. Oncol., July 1, 2004; 34(7): 369 - 378. [Abstract] [Full Text] [PDF] S. Dall'Ozzo, S. Tartas, G. Paintaud, G. Cartron, P. Colombat, P. Bardos, H. Watier, and G. Thibault Rituximab-Dependent Cytotoxicity by Natural Killer Cells: Influence of FCGR3A Polymorphism on the Concentration-Effect Relationship Cancer Res., July 1, 2004; 64(13): 4664 - 4669. [Abstract] [Full Text] [PDF] M. Ghielmini, S.-F. H. Schmitz, S. B. Cogliatti, G. Pichert, J. Hummerjohann, U. Waltzer, M. F. Fey, D. C. Betticher, G. Martinelli, F. Peccatori, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule Blood, June 15, 2004; 103(12): 4416 - 4423. [Abstract] [Full Text] [PDF] K. Tobinai, T. Igarashi, K. Itoh, Y. Kobayashi, M. Taniwaki, M. Ogura, T. Kinoshita, T. Hotta, K. Aikawa, K. Tsushita, et al. Japanese multicenter phase II and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma Ann. Onc., May 1, 2004; 15(5): 821 - 830. [Abstract] [Full Text] [PDF] C. Berger, C. A. Blau, M.-L. Huang, J. D. Iuliucci, D. C. Dalgarno, J. Gaschet, S. Heimfeld, T. Clackson, and S. R. Riddell Pharmacologically regulated Fas-mediated death of adoptively transferred T cells in a nonhuman primate model Blood, February 15, 2004; 103(4): 1261 - 1269. [Abstract] [Full Text] [PDF] O. Murillo, A. Arina, I. Tirapu, C. Alfaro, G. Mazzolini, B. Palencia, A. L.-D. De Cerio, J. Prieto, M. Bendandi, and I. Melero Potentiation of Therapeutic Immune Responses against Malignancies with Monoclonal Antibodies Clin. Cancer Res., November 15, 2003; 9(15): 5454 - 5464. [Abstract] [Full Text] [PDF] I. Jilani, S. O'Brien, T. Manshuri, D. A. Thomas, V. A. Thomazy, M. Imam, S. Naeem, S. Verstovsek, H. Kantarjian, F. Giles, et al. Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia Blood, November 15, 2003; 102(10): 3514 - 3520. [Abstract] [Full Text] [PDF] M. Coleman, D. M. Goldenberg, A. B. Siegel, J. C. Ketas, M. Ashe, J. M. Fiore, and J. P. Leonard Epratuzumab: Targeting B-Cell Malignancies through CD22 Clin. Cancer Res., September 1, 2003; 9(10): 3991s - 3994s. [Abstract] [Full Text] S. Shams'ili, J. Grefkens, B. de Leeuw, M. van den Bent, H. Hooijkaas, B. van der Holt, C. Vecht, and P. Sillevis Smitt Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients Brain, June 1, 2003; 126(6): 1409 - 1418. [Abstract] [Full Text] [PDF] B. C. Ekstrand, J. B. Lucas, S. M. Horwitz, Z. Fan, S. Breslin, R. T. Hoppe, Y. Natkunam, N. L. Bartlett, and S. J. Horning Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial Blood, June 1, 2003; 101(11): 4285 - 4289. [Abstract] [Full Text] [PDF] R. Schnell, P. Borchmann, J. O. Staak, J. Schindler, V. Ghetie, E. S. Vitetta, and A. Engert Clinical evaluation of ricin A-chain immunotoxins in patients with Hodgkin's lymphoma Ann. Onc., May 1, 2003; 14(5): 729 - 736. [Abstract] [Full Text] [PDF] J. Mangel, R. Buckstein, K. Imrie, D. Spaner, E. Franssen, P. Pavlin, A. Boudreau, N. Pennell, D. Combs, and N. L. Berinstein Pharmacokinetic study of patients with follicular or mantle cell lymphoma treated with rituximab as 'in vivo purge' and consolidative immunotherapy following autologous stem cell transplantation Ann. Onc., May 1, 2003; 14(5): 758 - 765. [Abstract] [Full Text] [PDF] J. A. Posey, T. C. Ng, B. Yang, M. B. Khazaeli, M. D. Carpenter, F. Fox, M. Needle, H. Waksal, and A. F. LoBuglio A Phase I Study of Anti-Kinase Insert Domain-containing Receptor Antibody, IMC-1C11, in Patients with Liver Metastases from Colorectal Carcinoma Clin. Cancer Res., April 1, 2003; 9(4): 1323 - 1332. [Abstract] [Full Text] [PDF] J. L. Rubenstein, D. Combs, J. Rosenberg, A. Levy, M. McDermott, L. Damon, R. Ignoffo, K. Aldape, A. Shen, D. Lee, et al. Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment Blood, January 15, 2003; 101(2): 466 - 468. [Abstract] [Full Text] [PDF] B. A. Peterson, G. R. Petroni, G. Frizzera, M. Barcos, C. D. Bloomfield, N. I. Nissen, D. D. Hurd, E. S. Henderson, G. P. Sartiano, J. L. Johnson, et al. Prolonged Single-Agent Versus Combination Chemotherapy in Indolent Follicular Lymphomas: A Study of the Cancer and Leukemia Group B J. Clin. Oncol., January 1, 2003; 21(1): 5 - 15. [Abstract] [Full Text] [PDF] H. E. Heslop, F. K. Stevenson, and J. J. Molldrem Immunotherapy of Hematologic Malignancy Hematology, January 1, 2003; 2003(1): 331 - 349. [Abstract] [Full Text] [PDF] J. C. Byrd, B. L. Peterson, V. A. Morrison, K. Park, R. Jacobson, E. Hoke, J. W. Vardiman, K. Rai, C. A. Schiffer, and R. A. Larson Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712) Blood, January 1, 2003; 101(1): 6 - 14. [Abstract] [Full Text] [PDF] J. A Krieger, J. M Merin, and I. Rabinowitz Necrotizing fasciitis following rituximab therapy Journal of Oncology Pharmacy Practice, December 1, 2002; 8(4): 127 - 129. [Abstract] [PDF] T. Igarashi, Y. Kobayashi, M. Ogura, T. Kinoshita, T. Ohtsu, Y. Sasaki, Y. Morishima, T. Murate, M. Kasai, N. Uike, et al. Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study Ann. Onc., June 1, 2002; 13(6): 928 - 943. [Abstract] [Full Text] [PDF] R. Schnell, O. Staak, P. Borchmann, C. Schwartz, B. Matthey, H. Hansen, J. Schindler, V. Ghetie, E. S. Vitetta, V. Diehl, et al. A Phase I Study with an Anti-CD30 Ricin A-Chain Immunotoxin (Ki-4.dgA) in Patients with Refractory CD30+ Hodgkin's and Non-Hodgkin's Lymphoma Clin. Cancer Res., June 1, 2002; 8(6): 1779 - 1786. [Abstract] [Full Text] [PDF] P. McLaughlin Progress and Promise in the Treatment of Indolent Lymphomas Oncologist, June 1, 2002; 7(3): 217 - 225. [Abstract] [Full Text] [PDF] J. W. J. van Esser, H. G. M. Niesters, B. van der Holt, E. Meijer, A. D. M. E. Osterhaus, J. W. Gratama, L. F. Verdonck, B. Lowenberg, and J. J. Cornelissen Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation Blood, May 29, 2002; 99(12): 4364 - 4369. [Abstract] [Full Text] [PDF] T. E. Witzig, L. I. Gordon, F. Cabanillas, M. S. Czuczman, C. Emmanouilides, R. Joyce, B. L. Pohlman, N. L. Bartlett, G. A. Wiseman, N. Padre, et al. Randomized Controlled Trial of Yttrium-90-Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin's Lymphoma J. Clin. Oncol., May 15, 2002; 20(10): 2453 - 2463. [Abstract] [Full Text] [PDF] I. M. Pedersen, A. M. Buhl, P. Klausen, C. H. Geisler, and J. Jurlander The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism Blood, February 15, 2002; 99(4): 1314 - 1319. [Abstract] [Full Text] [PDF] E Drewe and R J Powell Clinically useful monoclonal antibodies in treatment J. Clin. Pathol., February 1, 2002; 55(2): 81 - 85. [Abstract] [Full Text] [PDF] G. Cartron, L. Dacheux, G. Salles, P. Solal-Celigny, P. Bardos, P. Colombat, and H. Watier Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor Fcgamma RIIIa gene Blood, February 1, 2002; 99(3): 754 - 758. [Abstract] [Full Text] [PDF] A. Rambaldi, M. Lazzari, C. Manzoni, E. Carlotti, L. Arcaini, M. Baccarani, T. Barbui, C. Bernasconi, G. Dastoli, G. Fuga, et al. Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma Blood, February 1, 2002; 99(3): 856 - 862. [Abstract] [Full Text] [PDF] J. C. Byrd, S. Kitada, I. W. Flinn, J. L. Aron, M. Pearson, D. Lucas, and J. C. Reed The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction Blood, February 1, 2002; 99(3): 1038 - 1043. [Abstract] [Full Text] [PDF] B. Coiffier, E. Lepage, J. Briere, R. Herbrecht, H. Tilly, R. Bouabdallah, P. Morel, E. Van Den Neste, G. Salles, P. Gaulard, et al. CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma N. Engl. J. Med., January 24, 2002; 346(4): 235 - 242. [Abstract] [Full Text] [PDF] B. D. Cheson CHOP plus Rituximab -- Balancing Facts and Opinion N. Engl. J. Med., January 24, 2002; 346(4): 280 - 282. [Full Text] [PDF] A. M. Wu, G. J. Tan, M. A. Sherman, P. Clarke, T. Olafsen, S. J. Forman, and A. A. Raubitschek Multimerization of a chimeric anti-CD20 single-chain Fv-Fc fusion protein is mediated through variable domain exchange Protein Eng. Des. Sel., December 1, 2001; 14(12): 1025 - 1033. [Abstract] [Full Text] [PDF] C. L. Perez and S. Rudoy Anti-CD20 Monoclonal Antibody Treatment of Human Herpesvirus 8-Associated, Body Cavity-Based Lymphoma with an Unusual Phenotype in a Human Immunodeficiency Virus-Negative Patient Clin. Vaccine Immunol., September 1, 2001; 8(5): 993 - 996. [Abstract] [Full Text] [PDF] W.-K. Weng and R. Levy Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma Blood, September 1, 2001; 98(5): 1352 - 1357. [Abstract] [Full Text] [PDF] S. Alas and B. Bonavida Rituximab Inactivates Signal Transducer and Activation of Transcription 3 (STAT3) Activity in B-Non-Hodgkin's Lymphoma through Inhibition of the Interleukin 10 Autocrine/Paracrine Loop and Results in Down-Regulation of Bcl-2 and Sensitization to Cytotoxic Drugs Cancer Res., July 1, 2001; 61(13): 5137 - 5144. [Abstract] [Full Text] [PDF] J. C. Byrd, T. Murphy, R. S. Howard, M. S. Lucas, A. Goodrich, K. Park, M. Pearson, J. K. Waselenko, G. Ling, M. R. Grever, et al. Rituximab Using A Thrice Weekly Dosing Schedule in B-Cell Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Demonstrates Clinical Activity and Acceptable Toxicity J. Clin. Oncol., April 15, 2001; 19(8): 2153 - 2164. [Abstract] [Full Text] [PDF] S. Alas, C. Emmanouilides, and B. Bonavida Inhibition of Interleukin 10 by Rituximab Results in Down-Regulation of Bcl-2 and Sensitization of B-cell Non-Hodgkin's Lymphoma to Apoptosis Clin. Cancer Res., March 1, 2001; 7(3): 709 - 723. [Abstract] [Full Text] S. Depraetere, L. Verhoye, G. Leclercq, and G. Leroux-Roels Human B Cell Growth and Differentiation in the Spleen of Immunodeficient Mice J. Immunol., March 1, 2001; 166(5): 2929 - 2936. [Abstract] [Full Text] [PDF] J. M. Vose, B. K. Link, M. L. Grossbard, M. Czuczman, A. Grillo-Lopez, P. Gilman, A. Lowe, L. A. Kunkel, and R. I. Fisher Phase II Study of Rituximab in Combination With CHOP Chemotherapy in Patients With Previously Untreated, Aggressive Non-Hodgkin's Lymphoma J. Clin. Oncol., January 15, 2001; 19(2): 389 - 397. [Abstract] [Full Text] [PDF] O. W. Press, J. P. Leonard, B. Coiffier, R. Levy, and J. Timmerman Immunotherapy of Non-Hodgkin's Lymphomas Hematology, January 1, 2001; 2001(1): 221 - 240. [Abstract] [Full Text] [PDF] J. Yang, Q. Tao, I. W. Flinn, P. G. Murray, L. E. Post, H. Ma, S. Piantadosi, M. A. Caligiuri, and R. F. Ambinder Characterization of Epstein-Barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: disappearance after rituximab therapy does not predict clinical response Blood, December 15, 2000; 96(13): 4055 - 4063. [Abstract] [Full Text] [PDF] R. L. Ward, D. Packham, A. M. Smythe, J. Murray, P. Anderson-Stewart, N. Kitchen, R. Muirhead, P. Phillips, P. Gray, G. Bigg-Wither, et al. Phase I Clinical Trial of the Chimeric Monoclonal Antibody (c30.6) in Patients with Metastatic Colorectal Cancer Clin. Cancer Res., December 1, 2000; 6(12): 4674 - 4683. [Abstract] [Full Text] T. A. Davis, D. G. Maloney, A. J. Grillo-López, C. A. White, M. E. Williams, G. J. Weiner, S. Dowden, and R. Levy Combination Immunotherapy of Relapsed or Refractory Low-Grade or Follicular Non-Hodgkin's Lymphoma with Rituximab and Interferon-{{alpha}}-2a Clin. Cancer Res., July 1, 2000; 6(7): 2644 - 2652. [Abstract] [Full Text] J. Golay, L. Zaffaroni, T. Vaccari, M. Lazzari, G.-M. Borleri, S. Bernasconi, F. Tedesco, A. Rambaldi, and M. Introna Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis Blood, June 15, 2000; 95(12): 3900 - 3908. [Abstract] [Full Text] [PDF] P N Nelson, G M Reynolds, E E Waldron, E Ward, K Giannopoulos, and P G Murray Demystified ...: Monoclonal antibodies Mol. Pathol., June 1, 2000; 53(3): 111 - 117. [Abstract] [Full Text] J. M. Foran, A. Z. S. Rohatiner, D. Cunningham, R. A. Popescu, P. Solal-Celigny, M. Ghielmini, B. Coiffier, P. W. M. Johnson, C. Gisselbrecht, F. Reyes, et al. European Phase II Study of Rituximab (Chimeric Anti-CD20 Monoclonal Antibody) for Patients With Newly Diagnosed Mantle-Cell Lymphoma and Previously Treated Mantle-Cell Lymphoma, Immunocytoma, and Small B-Cell Lymphocytic Lymphoma J. Clin. Oncol., January 14, 2000; 18(2): 317 - 317. [Abstract] [Full Text] [PDF] T. A. Waldmann, R. Levy, and B. S. Coller Emerging Therapies: Spectrum of Applications of Monoclonal Antibody Therapy Hematology, January 1, 2000; 2000(1): 394 - 408. [Abstract] [Full Text] [PDF] R. Levy Karnofsky Lecture: Immunotherapy of Lymphoma J. Clin. Oncol., November 1, 1999; 17(90001): 7 - 12. [Full Text] [PDF] A. Protheroe, J. C. W. Edwards, A. Simmons, K. Maclennan, and P. Selby Remission of inflammatory arthropathy in association with anti-CD20 therapy for non-Hodgkin's lymphoma Rheumatology, November 1, 1999; 38(11): 1150 - 1152. [Abstract] [Full Text] [PDF] T. A. Davis, C. A. White, A. J. Grillo-Lopez, W. S. Velasquez, B. Link, D. G. Maloney, R. O. Dillman, M. E. Williams, A. Mohrbacher, R. Weaver, et al. Single-Agent Monoclonal Antibody Efficacy in Bulky Non-Hodgkin's Lymphoma: Results of a Phase II Trial of Rituximab J. Clin. Oncol., June 1, 1999; 17(6): 1851 - 1851. [Abstract] [Full Text] [PDF] T. A. Davis, D. K. Czerwinski, and R. Levy Therapy of B-Cell Lymphoma with Anti-CD20 Antibodies Can Result in the Loss of CD20 Antigen Expression Clin. Cancer Res., March 1, 1999; 5(3): 611 - 615. [Abstract] [Full Text] [PDF] M. S. Czuczman, A. J. Grillo-Lopez, C. A. White, M. Saleh, L. Gordon, A. F. LoBuglio, C. Jonas, D. Klippenstein, B. Dallaire, and C. Varns Treatment of Patients With Low-Grade B-Cell Lymphoma With the Combination of Chimeric Anti-CD20 Monoclonal Antibody and CHOP Chemotherapy J. Clin. Oncol., January 1, 1999; 17(1): 268 - 268. [Abstract] [Full Text] [PDF] M. A. Coccia and P. Brams High Titer, Prostate Specific Antigen-Specific Human IgG Production by hu-PBL-SCID Mice Immunized with Antigen-Mouse IgG2a Complex-Pulsed Autologous Dendritic Cells J. Immunol., November 15, 1998; 161(10): 5772 - 5780. [Abstract] [Full Text] [PDF] M. Benkerrou, J.-P. Jais, V. Leblond, A. Durandy, L. Sutton, P. Bordigoni, J. L. Garnier, J. Le Bidois, F. Le Deist, S. Blanche, et al. Anti-B-Cell Monoclonal Antibody Treatment of Severe Posttransplant B-Lymphoproliferative Disorder: Prognostic Factors and Long-Term Outcome Blood, November 1, 1998; 92(9): 3137 - 3147. [Abstract] [Full Text] [PDF] A. L. Tutt, R. R. French, T. M. Illidge, J. Honeychurch, H. M. McBride, C. A. Penfold, D. T. Fearon, R. M. E. Parkhouse, G. G. B. Klaus, and M. J. Glennie Monoclonal Antibody Therapy of B Cell Lymphoma: Signaling Activity on Tumor Cells Appears More Important Than Recruitment of Effectors J. Immunol., September 15, 1998; 161(6): 3176 - 3185. [Abstract] [Full Text] [PDF] B. Coiffier, C. Haioun, N. Ketterer, A. Engert, H. Tilly, D. Ma, P. Johnson, A. Lister, M. F. Buske, J.A. Radford, et al. Rituximab (Anti-CD20 Monoclonal Antibody) for the Treatment of Patients With Relapsing or Refractory Aggressive Lymphoma: A Multicenter Phase II Study Blood, September 15, 1998; 92(6): 1927 - 1932. [Abstract] [Full Text] [PDF] H. J. Haisma, M. F. Sernee, E. Hooijberg, R. H. Brakenhoff, I. H. v.d. Meulen-Muileman, H. M. Pinedo, and E. Boven Construction and Characterization of a Fusion Protein of Single-Chain Anti-CD20 Antibody and Human beta -Glucuronidase for Antibody-Directed Enzyme Prodrug Therapy Blood, July 1, 1998; 92(1): 184 - 190. [Abstract] [Full Text] [PDF] P. Brams, M.-L. Nguyen, S. Chamat, I. Royston, and P. R. Morrow Antigen-Specific IgG Responses from Naive Human Splenocytes: In Vitro Priming Followed by Antigen Boost in the SCID Mouse J. Immunol., March 1, 1998; 160(5): 2051 - 2058. [Abstract] [Full Text] [PDF] D. Shan, J. A. Ledbetter, and O. W. Press Apoptosis of Malignant Human B Cells by Ligation of CD20 With Monoclonal Antibodies Blood, March 1, 1998; 91(5): 1644 - 1652. [Abstract] [Full Text] [PDF] D. G. Maloney, A. J. Grillo-Lopez, C. A. White, D. Bodkin, R. J. Schilder, J. A. Neidhart, N. Janakiraman, K. A. Foon, T.-M. Liles, B. K. Dallaire, et al. IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma Blood, September 15, 1997; 90(6): 2188 - 2195. [Abstract] [Full Text] [PDF] J. L. Hornick, L. A. Khawli, P. Hu, M. Lynch, P. M. Anderson, and A. L. Epstein Chimeric CLL-1 Antibody Fusion Proteins Containing Granulocyte-Macrophage Colony-Stimulating Factor or Interleukin-2 With Specificity for B-Cell Malignancies Exhibit Enhanced Effector Functions While Retaining Tumor Targeting Properties Blood, June 15, 1997; 89(12): 4437 - 4447. [Abstract] [Full Text] [PDF]

	Copyright © 1994 by American Society of Hematology         Online ISSN: 1528-0020